E-Business Library > NJSLA Jobs: Scientific Knowledge Management Specialist
[NJSLA Jobs] Merck Manufacturing Division's GSTC organization is accountable for stewardship of manufacturing technologies within Merck and either directly accountable or supporting the late stage product and process development, commercialization, launch and support of Merck's pharmaceuticals, consumer care, vaccines and biologics. It also oversees a commercialization network of sites across the globe that directly manufactures experimental and commercial supplies for Merck.
[Previous] Knowledge Management & Learning Organisation: Six of on...
[Next] The Cloud's Answer to the Knowledge Management Challenge...
Some related posts from Technorati and Google.
[Merck Experienced - Project Management & Director Jobs] Device Commercialization Manager Job (Rahway, NJ, US): All resumes submitted by search firms to any employee at Merck via-email, the Internet or in any form and/or method without a valid written search agreement in place for this position will be deemed the sole property of Merck. No fee will be paid in the event the candidate is hired by Merck as a result of the referral or through other means.
[blog.bioethics.net] Merck Makes Phony Peer-Review Journal | blog.bioethics.net: The fact that a company like Merck sites studies published in a journal from Australasia should clue you in on something being fishy. I don't think scientists with elementary knowledge of journals would give credit to these kinds of gimmicks more than a glimpse, especially if they are citing such outstanding results of a product marketed to Europe and North America.
[News from The Scientist] Elsevier published 6 fake journals - The Scientist - Magazine of ...: The allegations involve the Australasian Journal of Bone and Joint Medicine, a publication paid for by pharmaceutical company Merck that amounted to a compendium of reprinted scientific articles and one-source reviews, most of which presented data favorable to Merck's products. The Scientist obtained two 2003 issues of the journal -- which bore the imprint of Elsevier's Excerpta Medica -- neither of which carried a statement obviating Merck's sponsorship of the publication.
[Nat's Jobs.com] Jobs in Boston, MA (05/16/09): Hosted by the show's namesake, Straka will spend the 30 minute timeslot interviewing fighters and other MMA-affiliated personalities, beginning with Dana …
[www.jerseyonsale.com] http://www.b2bjersey.com: Whatour Is the court saying that it doesn’t need to discuss 230 because Stayart failed to state a valid IP claim, or is the court saying that Yahoo qualifies for the 230 immunity because doing so would be consistent with 230’s policies–even if the court has to ignore 230’s statutory exclusion for IP claimsour The court could have found a role for 230 by concluding that the Lanham Act false endorsement claim wasn’t really an IP claim at all, any more than a Lanham Act false advertising claim is an IP claim, but I don’t think the court said that.
[Pharmaceutical Executive Magazine] The New Breed of Leadership: Tomorrow's biopharma business will be built around two pillars: people and perceptions. One cannot stand without the other. No industry focused on the commercialization of intangibles like scientific knowledge can thrive unless .... tional intelligence, situational management, and other fashion- able phrases make his soft list, but so do time-honored talents as communication and inspiration and such outmoded traits as accountability. “You have to walk the talk and model ...
[The Cutter Blog] The Cutter Blog » Blog Archive » Choking on “One Throat to Choke”: Because they probably have a well-orchestrated set of activities regarding complex vendor management. IT shops that can manage greater complexities can help their firms manage complex competitive environments.
[News from The Scientist] Contract research on the rise - The Scientist - Magazine of the ...: In both cases, Zhang said, this growth stems primarily from a cost advantage to doing business in China, both in physician salaries and healthcare costs, as well as what she calls the "patient advantage." In the US, patients -- especially those with health insurance -- are reluctant to participate in clinical trials. "In China," she said, "we have 1.3 billion people, [most of whom] don't have good access to the health care system." Participating in a study is often their best chance for treatment.
Reflected tags on Technorati: Blog, Knowledge Management, E-Business Library